DATE OF REQUEST:				
CLIENT INFORMATION:				
Client Name (Last, First, M):				
District/Clinic where the client is seen:				
Client/Caregiver:				
1) Patient is willing to take (or caregiver to administer) medications as directed.				
2) Patient has prior evidence of adherence to therapy and medical care; and prescriber has reasonable expectation that adherent behavior will continue.				
3) Patient's home has sufficient storage at the proper temperature.				
DRUGS REQUESTED & REQUIRED INFORMATION:				
Please complete the corresponding section for the specific drugs requested and check the appropriate boxes, or supply the response/supporting documentation.				
Fuzeon (Enfuviritide)				
1) Current antiretroviral regimen:				
2) Please attach copies of the most recent viral load, CD4 count and all available resistance testing.				
3) Proposed optimized regimen:				
4) Does the client have a history of moderate to severe adverse events/intolerances/				
- If yes, what medications?				
- Describe the reaction:				
5) Does the client have a history of enrollment in a recent study or Expanded Access Program? (<i>If yes, please provide documentation.</i>)				
If a client's regimen includes Fuzeon, the Georgia ADAP recommends completing a "Fuzeon Nurse Connections" enrollment form to arrange for a home visit from a Fuzeon Nurse Educator to help the client to become confident in their ability to reconstitute and inject Fuzeon. The form is available at www.fuzeon.com or via phone at 877-4FUZEON (877-438-9366).				
Selzentry (Maraviroc)				
1) Current antiretroviral regimen:				
2) Please attach copies of the most recent viral load, CD4 count, tropism assay test, and all available resistance testing.				
3) Proposed optimized regimen:				

4) Does the client have a history of moderate to severe adverse events/intolerances/				
- If yes, what medications?				
- Describe the reaction:				
Videx (Didanosine)				
1) Current antiretroviral regimen:				
2) Length of time on current regimen:				
3) Reason for continuing or adding Videx to the regimen:				
4) Please attach copies of the most recent viral load, CD4 count and all available resistance testing.				
Zerit (Stavudine)				
1) Current antiretroviral regimen:				
2) Length of time on current regimen:				
3) Reason for continuing or adding Zerit to the regimen:				
4) Please attach copies of the most recent viral load, CD4 count and all available resistance testing.				
Please select requested regimen from the options listed below. (Ribavirin will be weight based.): Harvoni (Ledipasvir-sofosbuvir) Daklinza (Daclatasvir) plus Sovaldi (Sofosbuvir) with Ribavirin or Sovaldi (Sofosbuvir) plus Ribavirin VIEKIRA PAK with Ribavirin or with Ribavirin or without Ribavirin Technivie with Ribavirin or without Ribavirin without Ribavirin				
Requested Course of Therapy: 12 weeks, 16 weeks, or 24 weeks				
1) Client is an active and stable ADAP client. (<i>Requirement</i>) Yes				
2) Client Weight: 3) Client Age: 4) Client Sex:				
5) Current antiretroviral regimen:				
6) List of current non-HIV medications:				

7) Does the client have a history of moderate to severe adverse events/intolerances/				
- If yes, what medications?				
- Describe the reaction:				
8) Please attach copies of the most recent lab work: HIV viral load, CD4 count, CMP, CBC, PT/INR, pregnancy test (if woman of child bearing age), Hepatitis C antibody, Hepatitis C viral load, NS5A resistance-associated polymorphism test (for Zepatier: genotype 1a), Hepatitis C genotype/subtype, i.e. 1a, 1b, etc. In addition, all clients initiating HCV therapy should be assessed for HBV coinfection with HBsAg, anti-HBs, and anti-HBc, as per current AALSD guidelines and FDA Safety Announcement.				
9) Hepatitis C Stage: $\Box 0 \Box 1 \Box 2 \Box 3 \Box 4$	compensated c	irrhosis 🗌 decoi	mpensated cirrhos	sis
- Please check the lab performed within the last 1	2 months and incl	ude a copy:		
Liver Biopsy FIB-4 Calculation		Non-Invasive	e Biomarker Testi	ng
10) Please attach the client's MELD or Child-Pugh sc	ore.			
11) Does the client have a history of Hepatitis C treat	ment?		🗌 Yes 🔲 N	No
- If yes, what treatment?				
12) The requesting provider is asking the State Medical Advisor to make the treatment recommendation.				
Provider/Prescriber Guidelines:				
Provider/Prescriber Guidelines:				
Patient must have a repeat HIV viral load and CD4 corregimen to assess effectiveness.	-			e
Patient must have a repeat HIV viral load and CD4 coregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i	mprovement (or c	linically stable if		e
Patient must have a repeat HIV viral load and CD4 corregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuation	mprovement (or c on of the new regi	linically stable if	condition was	
Patient must have a repeat HIV viral load and CD4 corregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuati The prescriber must review the state guidelines and/or determine that the patient qualifies.	mprovement (or c on of the new reg restrictions conce	linically stable if imen. erning the use of	condition was	
Patient must have a repeat HIV viral load and CD4 corregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuation The prescriber must review the state guidelines and/or determine that the patient qualifies. The prescriber should be an experiences HIV/AIDS p	mprovement (or c on of the new regi restrictions conce rovider or should	linically stable if imen. erning the use of consult with a sp	condition was	
Patient must have a repeat HIV viral load and CD4 corregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuati The prescriber must review the state guidelines and/or determine that the patient qualifies. The prescriber should be an experiences HIV/AIDS p have sufficient office/clinic capability to provide patient	mprovement (or c on of the new regi restrictions conce rovider or should ent education and	linically stable if imen. erning the use of consult with a sp monitoring.	condition was	
Patient must have a repeat HIV viral load and CD4 corregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuati The prescriber must review the state guidelines and/or determine that the patient qualifies. The prescriber should be an experiences HIV/AIDS p have sufficient office/clinic capability to provide patien Guidelines: http://aidsinfo.nih.gov/guidelines / https://	mprovement (or c on of the new regi restrictions conce rovider or should ent education and (dph.georgia.gov/n	linically stable if imen. erning the use of consult with a sp monitoring.	condition was	
Patient must have a repeat HIV viral load and CD4 coregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuati The prescriber must review the state guidelines and/or determine that the patient qualifies. The prescriber should be an experiences HIV/AIDS p have sufficient office/clinic capability to provide patie Guidelines: http://aidsinfo.nih.gov/guidelines / https://Hepatitis C Guidelines: http://www.hcvguidelines.org	mprovement (or c on of the new regi restrictions conce rovider or should ent education and (dph.georgia.gov/n /	linically stable if imen. erning the use of consult with a sp monitoring. hurse-protocols	condition was these medications ecialist and must	
Patient must have a repeat HIV viral load and CD4 coregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuati The prescriber must review the state guidelines and/or determine that the patient qualifies. The prescriber should be an experiences HIV/AIDS p have sufficient office/clinic capability to provide patie Guidelines: <u>http://aidsinfo.nih.gov/guidelines / https:/</u> Hepatitis C Guidelines: <u>http://www.hcvguidelines.org</u> Georgia Department of Public Health Hepatitis C Tes dph.georgia.gov/files/related_files/site_page/	mprovement (or c on of the new regi restrictions conce rovider or should ent education and (dph.georgia.gov/n / ting Toolkit: https	linically stable if imen. erning the use of consult with a sp monitoring. nurse-protocols ://dph.georgia.go	condition was these medications ecialist and must	
Patient must have a repeat HIV viral load and CD4 coregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuati The prescriber must review the state guidelines and/or determine that the patient qualifies. The prescriber should be an experiences HIV/AIDS p have sufficient office/clinic capability to provide patie Guidelines: http://aidsinfo.nih.gov/guidelines / https://Hepatitis C Guidelines: http://www.hcvguidelines.org Georgia Department of Public Health Hepatitis C Tes	mprovement (or c on of the new regi restrictions conce rovider or should ent education and (dph.georgia.gov/n / ting Toolkit: https	linically stable if imen. erning the use of consult with a sp monitoring. nurse-protocols ://dph.georgia.go	condition was these medications ecialist and must	
Patient must have a repeat HIV viral load and CD4 coregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuati The prescriber must review the state guidelines and/or determine that the patient qualifies. The prescriber should be an experiences HIV/AIDS p have sufficient office/clinic capability to provide patie Guidelines: http://aidsinfo.nih.gov/guidelines / https://Hepatitis C Guidelines: http://www.hcvguidelines.org Georgia Department of Public Health Hepatitis C Tes dph.georgia.gov/files/related_files/site_page/ADES_Hepatitis_C_Testing_Toolkit_for_Primary_C FDA Drug Safety Communication: FDA warns about	mprovement (or c on of the new regi restrictions conce rovider or should ent education and (dph.georgia.gov/n / ting Toolkit: https are_Providers_in_ the risk of Hepati	linically stable if imen. erning the use of consult with a sp monitoring. nurse-protocols ://dph.georgia.go Georgia.pdf tis B reactivating	condition was these medications ecialist and must ov/sites/ g in some patients	s to
Patient must have a repeat HIV viral load and CD4 coregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuati The prescriber must review the state guidelines and/or determine that the patient qualifies. The prescriber should be an experiences HIV/AIDS p have sufficient office/clinic capability to provide patie Guidelines: http://aidsinfo.nih.gov/guidelines / https://Hepatitis C Guidelines: http://www.hcvguidelines.org Georgia Department of Public Health Hepatitis C Tes dph.georgia.gov/files/related_files/site_page/ADES_Hepatitis_C_Testing_Toolkit_for_Primary_C	mprovement (or c on of the new regi restrictions conce rovider or should ent education and /dph.georgia.gov/n / ting Toolkit: https are_Providers_in_ the risk of Hepati C: http://www.fda	linically stable if imen. erning the use of consult with a sp monitoring. nurse-protocols ://dph.georgia.go Georgia.pdf tis B reactivating gov/Drugs/Drug	condition was these medications ecialist and must ov/sites/ g in some patients	s to
Patient must have a repeat HIV viral load and CD4 coregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuati The prescriber must review the state guidelines and/or determine that the patient qualifies. The prescriber should be an experiences HIV/AIDS p have sufficient office/clinic capability to provide patied Guidelines: http://aidsinfo.nih.gov/guidelines / https://Hepatitis C Guidelines: http://www.hcvguidelines.org Georgia Department of Public Health Hepatitis C Testing_Toolkit_for_Primary_C FDA Drug Safety Communication: FDA warns about treated with direct-acting antiretrovirals for Hepatitis	mprovement (or c on of the new regi restrictions conce rovider or should ent education and /dph.georgia.gov/n / ting Toolkit: https are_Providers_in_ the risk of Hepati C: http://www.fda	linically stable if imen. erning the use of consult with a sp monitoring. nurse-protocols ://dph.georgia.go Georgia.pdf tis B reactivating gov/Drugs/Drug	condition was these medications ecialist and must ov/sites/ g in some patients	s to
Patient must have a repeat HIV viral load and CD4 coregimen to assess effectiveness. If CD4 and/or viral load have not improved, clinical i worsening before) must be documented for continuati The prescriber must review the state guidelines and/or determine that the patient qualifies. The prescriber should be an experiences HIV/AIDS p have sufficient office/clinic capability to provide patie Guidelines: http://aidsinfo.nih.gov/guidelines / https:// Hepatitis C Guidelines: http://www.hcvguidelines.org Georgia Department of Public Health Hepatitis C Tes dph.georgia.gov/files/related_files/site_page/ ADES_Hepatitis_C_Testing_Toolkit_for_Primary_C FDA Drug Safety Communication: FDA warns about treated with direct-acting antiretrovirals for Hepatitis ucm522932.htm?source=govdelivery&utm_medium=	mprovement (or c on of the new regi restrictions conce rovider or should ent education and /dph.georgia.gov/n / ting Toolkit: https are_Providers_in_ the risk of Hepati C: http://www.fda	linically stable if imen. erning the use of consult with a sp monitoring. nurse-protocols ://dph.georgia.go Georgia.pdf tis B reactivating gov/Drugs/Drug	condition was these medications ecialist and must ov/sites/ g in some patients	s to

Request Determination:				
Date Received:	Date of Decision:			
Request approved Request Denied				
Medical Advisor (Last, First, M):				
Phone: En	nail:			
Medical Advisor/ Prescriber Signature:				
Comments/Additional Information or Instructions:				